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Background: Creatine transporter deficiency (CTD) is a treatable, X-linked, inborn error of
metabolism. Case characteristics: Two brothers with autism spectrum disorder were
diagnosed with CTD at the ages of 17 and 12 years. Both were found to have a previously
reported hemizygous p.408delF (c.1216_1218delTTC) deletion mutation. Outcome: Both
patients were given creatine monohydrate, L-arginine, L-glycine and S-
adenosylmethionine, which partially improved the behavioral problems.  Message: Serum
creatinine levels, creatine peak at brain MR spectroscopy or creatine/creatinine ratio in urine
should be evaluated to identify CTD in children with autistic behavior and language
disorders.
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Creatine transporter deficiency (CTD; OMIM300352) is an X-linked inborn error ofmetabolism caused by mutations in thecreatine transporter gene (SLC6A8). SLC6A8
gene mutations impair the ability of the transporter
protein to bring creatine into cells, resulting in a creatine
deficiency in organs and tissues that require large
amounts of energy, especially the brain [1]. Its clinical
hallmarks are intellectual disability (ID), epilepsy,
autistic behavior, and language disorders [2]. In this
report, we describe the diagnosis and treatment of CTD in
two brothers who received mild benefits from therapy
despite being diagnosed late.
CASE REPORT
The patients were two brothers, aged 17 and 12 years,
from a non-consanguineous marriage with an uneventful
perinatal history. Their mother did not exhibit behavioral
or learning difficulties. The parents first noticed a
developmental delay in the older brother at one year of
age. He was diagnosed with autism spectrum disorder
according to the DSM-IV criteria at the age of 2.5 years
with signs of ID, severely delayed speech development,
communication difficulties, swinging his trunk from side
to side and a tendency to play by himself. He had four
generalized tonic-clonic convulsions at seven years of
age and was given valproic acid. Similarly, a
developmental delay was noticed in the younger brother
in his first months of life. He was diagnosed with autism
at one year of age. He had a single generalized tonic-
clonic convulsion at 10 years of age that was not repeated
after the initiation of levetiracetam. Electro-
encephalograms were normal for both patients.
Physical examination at admission showed no verbal
expression and limited non-verbal communication with
poor eye contact and inconsistent responses to instruc-
tions in both siblings. The parents noted that both siblings
experienced screaming, hitting, and biting, but not self-
mutilation. Other physical and clinical observations were
normal without microcephaly, dysmorphy, hypotonia,
myopathy, or movement disorders. They could not
complete formal cognitive testing due to severe cognitive
impairment.
Metabolic evaluations were normal with exception of
mild pyruvic acid, 3-methylglutaconic acid, and succinic
acid excretion in urine in the younger sibling. Brain MRI
showed mild cerebral atrophy and mild thinning of the
corpus callosum in both patients. Brain MR spectroscopy
(MRS) of the patients indicated markedly decreased creatine
levels in the basal ganglia and white matter. Plasma levels of
creatinine were normal (0.50 and 0.45 mg/dL, respectively),
and urine creatine/creatinine ratios were increased (1.84 and
1.48, respectively normal: 0.01-0.96). Guanidinoacetate
levels in the urine were normal (49.0 and 36.0 mmol/mol
creatinine, respectively; normal: 28-180). SLC6A8 gene
sequencing showed a hemizygous c.1216_ 1218delTTC
deletion in exon 8, which resulted in the deletion of a
phenylalanine (p.Phe408del). Both patients were treated
with creatine monohydrate (per oral 400 mg/kg/day), L-
arginine and L-glycine for 14 months. S-adenosylmethionine
was discontinued because of side effects.
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DISCUSSION
The reported prevalence of IEMs in autism ranges
between 0.5-2.7%. It is recommended to rule out
metabolic disorders in autistic patients who have
dysmorphism, microcephaly, ataxia, epilepsy, and severe
ID, but not in patients with non-syndromic autism [3,4].
The metabolic investigations used for autism are serum
creatinine, cholesterol, lactate, ammonia, amino acids,
acylcarnitine, urine mucopolysaccharides, and organic
acids [5]. The serum creatinine level should be
determined in autistic children to diagnose Cerebral
creatine deficiency syndromes (CDS) characterized by
developmental delays, seizures, and autism. CDS can be
caused by three different inborn errors of creatine
synthesis and transport. The plasma creatinine level is
low in patients with creatine synthesis defects, which are
autosomal recessive diseases. However, this level is
normal in patients with CTD. In all cases of CDS, creatine
levels are low in brain tissue, as detected by MRS [6]. The
serum creatinine levels of the siblings were normal, but
their creatine levels in brain tissue were low. Urinary
guanidinoacetate level and creatine/creatinine ratio are
used for the differential diagnosis of CDS [6]. In both
patients, the urine creatine/creatinine ratio was increased,
and the urine guanidinoacetate level was normal, which is
consistent with CTD.
The hemizygous deletion mutation (p.Phe408del)
detected in the siblings has been associated with a partial
or even complete loss of creatine transport function.
Previously described patients with the same mutation
were presented with autistic behavior pattern, severe
language delay and epilepsy, as in our patients [2].
Treatment with creatine, L-arginine, and L-glycine
reduced the anxiety, aggressiveness, and screaming
episodes experienced by the younger sibling, but not the
older sibling. We could not assess the effect of treatment
on epilepsy because neither sibling had any convulsions
after the initiation of antiepileptic drugs, and their
electroencephalograms were normal before the
treatment. Prior studies have reported that this treatment
regimen can improve both behavioral and language
difficulties, but we did not observe any improvements in
the language skills of the patients [6]. S-
adenosylmethionine was withdrawn because it increased
restlessness and anxiety and reduced sleeping time when
the dose was increased to 10 mg/kg/day.
Diagnosing IEMs early in life is essential for
achieving prenatal diagnosis and early institution of
treatment. Serum creatinine levels should be checked
carefully in all patients with hypotonia, developmental
delay, seizure, or autism to diagnose creatine synthesis
defects, as early treatment results in excellent outcomes.
In autistic patients whose serum creatinine levels are
normal, if additional clinical findings such as hypotonia,
developmental delay and epilepsy are present, this
approach should be followed by determination of
creatine peak in brain tissue by MRS in addition to other
metabolic investigations.
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